Jürgen Grünberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3560521/publications.pdf

Version: 2024-02-01

38 2,311 26 37
papers citations h-index g-index

38 38 38 2274
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Siteâ€Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase. Angewandte Chemie - International Edition, 2010, 49, 9995-9997.	13.8	274
2	The Alzheimer's Disease-Associated Presenilins Are Differentially Phosphorylated Proteins Located Predominantly within the Endoplasmic Reticulum. Molecular Medicine, 1996, 2, 673-691.	4.4	230
3	Presenilins Are Processed by Caspase-type Proteases. Journal of Biological Chemistry, 1997, 272, 20655-20659.	3.4	142
4	Efficient Inhibition of Intra-Peritoneal Tumor Growth and Dissemination of Human Ovarian Carcinoma Cells in Nude Mice by Anti-L1-Cell Adhesion Molecule Monoclonal Antibody Treatment. Cancer Research, 2006, 66, 936-943.	0.9	140
5	The low-energy $\hat{l}^2\hat{a}$ and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy. Nuclear Medicine and Biology, 2011, 38, 917-924.	0.6	120
6	Zebrafish ($\langle i \rangle$ Danio rerio $\langle i \rangle$) Presenilin Promotes Aberrant Amyloid \hat{l}^2 -Peptide Production and Requires a Critical Aspartate Residue for Its Function in Amyloidogenesis. Biochemistry, 1999, 38, 13602-13609.	2.5	118
7	Mutant Presenilin 2 Transgenic Mouse: Effect on an Ageâ€Dependent Increase of Amyloid βâ€Protein 42 in the Brain. Journal of Neurochemistry, 1998, 71, 313-322.	3.9	81
8	Cellular Expression and Proteolytic Processing of Presenilin Proteins Is Developmentally Regulated During Neuronal Differentiation. Journal of Neurochemistry, 1997, 69, 2432-2440.	3.9	79
9	In vivo Evaluation of 177Lu- and 67/64Cu-Labeled Recombinant Fragments of Antibody chCE7 for Radioimmunotherapy and PET Imaging of L1-CAM-Positive Tumors. Clinical Cancer Research, 2005, 11, 5112-5120.	7.0	79
10	Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. NeuroReport, 1998, 9, 1481-1486.	1.2	75
11	Structural Determinants Required for Apical Sorting of an Intestinal Brush-border Membrane Protein. Journal of Biological Chemistry, 2000, 275, 6566-6572.	3.4	74
12	Copper-67 Radioimmunotherapy and Growth Inhibition by Anti–L1-Cell Adhesion Molecule Monoclonal Antibodies in a Therapy Model of Ovarian Cancer Metastasis. Clinical Cancer Research, 2007, 13, 603-611.	7.0	73
13	Alzheimer's Disease Associated Presenilin-1 Holoprotein and Its 18â^20 kDa C-Terminal Fragment Are Death Substrates for Proteases of the Caspase Familyâ€. Biochemistry, 1998, 37, 2263-2270.	2.5	69
14	Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nuclear Medicine and Biology, 2003, 30, 417-427.	0.6	68
15	Proteolytic Fragments of the Alzheimer's Disease Associated Presenilins-1 and -2 Are Phosphorylated in Vivo by Distinct Cellular Mechanismsâ€. Biochemistry, 1998, 37, 5961-5967.	2.5	60
16	Future prospects for SPECT imaging using the radiolanthanide terbium-155 â€" production and preclinical evaluation in tumor-bearing mice. Nuclear Medicine and Biology, 2014, 41, e58-e65.	0.6	60
17	Modification of Different IgC1 Antibodies via Glutamine and Lysine using Bacterial and Human Tissue Transglutaminase. Bioconjugate Chemistry, 2008, 19, 271-278.	3.6	54
18	Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1907-1915.	6.4	51

#	Article	IF	CITATIONS
19	The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. International Journal of Biochemistry and Cell Biology, 2009, 41, 1572-1580.	2.8	49
20	Novel Therapeutic Strategies for Ovarian Cancer Stem Cells. Frontiers in Oncology, 2020, 10, 319.	2.8	44
21	Expression of the alpha subunit of PABA peptide hydrolase (EC 3.4.24.18) in MDCK cells. FEBS Letters, 1993, 335, 376-379.	2.8	39
22	Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties. Nuclear Medicine and Biology, 2006, 33, 883-889.	0.6	39
23	High-Yield Production of Recombinant Antibody Fragments in HEK-293 Cells Using Sodium Butyrate. BioTechniques, 2003, 34, 968-972.	1.8	37
24	Hepatocyte Growth Factor-induced Ectodomain Shedding of Cell Adhesion Molecule L1. Journal of Biological Chemistry, 2004, 279, 31149-31156.	3.4	32
25	L1â€CAMâ€targeted antibody therapy and ¹⁷⁷ Luâ€radioimmunotherapy of disseminated ovarian cancer. International Journal of Cancer, 2012, 130, 2715-2721.	5.1	31
26	DOTA-Functionalized Polylysine: A High Number of DOTA Chelates Positively Influences the Biodistribution of Enzymatic Conjugated Anti-Tumor Antibody chCE7agl. PLoS ONE, 2013, 8, e60350.	2.5	28
27	Antibodies directed against L1-CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells. Cancer Letters, 2008, 261, 193-204.	7.2	25
28	L1 Cell Adhesion Molecule Confers Radioresistance to Ovarian Cancer and Defines a New Cancer Stem Cell Population. Cancers, 2020, 12, 217.	3.7	23
29	Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies. Journal of Neuroscience Research, 1999, 56, 405-419.	2.9	20
30	Proteolytic Processing of Human Lactase-Phlorizin Hydrolase Is a Two-Step Event: Identification of the Cleavage Sites. Archives of Biochemistry and Biophysics, 1996, 336, 27-34.	3.0	18
31	Truncated presenilin 2 derived from differentially spliced mRNAs does not affect the ratio of amyloid \hat{l}^2 -peptide 1-42/1-40. NeuroReport, 1998, 9, 3293-3299.	1.2	17
32	Proteolytic processing of human intestinal lactase-phlorizin hydrolase precursor is not a prerequisite for correct sorting in Madin Darby canine kidney (MDCK) cells. FEBS Letters, 1992, 314, 224-228.	2.8	16
33	Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model. EJNMMI Research, 2014, 4, 54.	2.5	13
34	Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma. BMC Cancer, 2018, 18, 922.	2.6	10
35	Human Lactase–Phlorizin Hydrolase: Evidence of Dimerization in the Endoplasmic Reticulum. Archives of Biochemistry and Biophysics, 1995, 323, 367-372.	3.0	8
36	Radiopharmaceuticals: From Molecular Imaging to Targeted Radionuclide Therapy. Chimia, 2004, 58, 731-735.	0.6	8

#	Article	IF	CITATIONS
37	Imaging of renal carcinoma xenografts with 64 Cu-labelled anti-L1-CAM antibody chCE7. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1066-1066.	6.4	4
38	Radiometal Labeling of Antibodies and Antibody Fragments for Imaging and Therapy., 2004, 248, 481-494.		3